The $25 million facility more than doubles the previous MDS Phase I capacity in Phoenix to 420 total beds to meet the growing needs of its pharmaceutical and biotech clients. Part of an extensive global network of European and North American Phase I locations, the new facility brings the MDS Pharma Services global total to more than 1,100 beds.
Purpose-built from the ground up to be a Phase I clinic, the new facility has a state-of-the art clinical lab and secure pharmacy, comfortable accommodations for study participants and well-appointed areas for visiting clients. The workforce for the new facility is drawn from the same experienced team that operated the earlier MDS Pharma Services Phoenix clinic, where they achieved a better than 97% on-time study start-up record.